Hikma awarded Global Generics Acquisition of the Year

London, 14 October 2015 – Hikma Pharmaceuticals PLC (“Hikma”) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY), (rated Ba1 Moody’s / BB+ S&P , both stable) the fast growing multinational pharmaceutical group is pleased to announce that it was the recipient of the “Acquisition of the Year Award” at the Global Generics and Biosimilars Awards held in Madrid on 13 October 2015. The award was given in recognition of Hikma’s acquisition of Roxane Laboratories Inc. from Boehringer Ingelheim, which will transform Hikma’s non-injectables business in the US, adding complementary and well differentiated products, an attractive pipeline, proven R&D capabilities and greater overall scale.